Skip to content

Artiva Biotherapeutics, Inc. ARTV Other income, net (Note 6)

Other income, net (Note 6) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$32M+90.6%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
-$21K+22.2%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$212K+130%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$62K+27.1%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$336K-226%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue-
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-67.9%
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s other income, net (note 6)?
Artiva Biotherapeutics, Inc. (ARTV) reported other income, net (note 6) of $2K in Q1 2026.
How has Artiva Biotherapeutics, Inc.'s other income, net (note 6) changed year-over-year?
Artiva Biotherapeutics, Inc.'s other income, net (note 6) increased by 150.0% year-over-year, from -$4K to $2K.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.